整块钬激光前列腺剜除术与机器人辅助单纯前列腺切除术围手术期及短期结局比较:倾向性评分匹配分析
本研究回顾性分析两家高容量中心2017至2022年接受整块钬激光前列腺剜除术(HoLEP)或机器人辅助单纯前列腺切除术(RASP)的患者,经倾向性评分匹配后比较48例HoLEP与47例RASP。HoLEP组手术时间、住院时间、导尿时间更短,早期并发症率及血红蛋白下降更低;RASP组术后顺行射精率、1个月最大尿流率和控尿率更优;两组Trifecta率相似。
要点
- HoLEP组住院时间中位数4天 vs RASP组5天,导尿时间中位数3天 vs 2天,HoLEP更短(p<0.05)。
- HoLEP组早期并发症率6.2% vs RASP组12.6%(p=0.03),血红蛋白下降1.4 vs 2.4 g/dL(p=0.03)。
- RASP组术后顺行射精55.3% vs HoLEP组6.8%,1个月最大尿流率中位数28 vs 24 ml/sec,控尿率0% vs 20.8%(p<0.05)。
核心结论
- HoLEP和RASP均为症状性BPH安全有效的治疗方式;HoLEP围手术期风险更低但短暂早期尿失禁概率更高,RASP在减少术后射精功能障碍方面更有效。
研究设计与样本
- 回顾性查询两家高容量中心2017至2022年前瞻性数据库,纳入接受HoLEP或RASP的患者,基于IPSS问卷、前列腺体积和最大尿流率进行倾向性评分匹配,每个中心由单一术者完成手术。
- 匹配后共48例HoLEP和47例RASP;术后1、3、6个月评估结局,此后每年评估。
主要发现
- HoLEP组手术时间、住院时间(中位数4 vs 5天)和导尿时间(中位数3 vs 2天)均短于RASP组(p<0.05)。
- HoLEP组早期术后并发症率6.2% vs RASP组12.6%(p=0.03),术后血红蛋白下降1.4 vs 2.4 g/dL(p=0.03)。
- RASP组术后顺行射精55.3% vs HoLEP组6.8%,1个月最大尿流率中位数28 vs 24 ml/sec,控尿率0% vs 20.8%,均优于HoLEP组(p<0.05)。
- 两组Trifecta率相似(76.1% vs 82.6%)。
关键数值与推荐
- Trifecta定义为同时满足:a)术后第一个月内无并发症;b)术后1个月Qmax>15 ml/s;c)3个月评估时无尿失禁。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgical treatment of symptomatic benign prostatic hyperplasia (BPH) has seen an evolution during the last decades. On one hand, en-bloc HoLEP emerged as a valid endoscopic treatment regardless prostate size. On the other hand, robot-assisted simple prostatectomy (RASP) has gained attention in larger prostates showing encouraging results. Herein, for the first time in the scientific scenario, we sought to compare the outcomes of RASP and en-bloc HoLEP cases after propensity-score matching (PSM) analysis. METHODS: We retrospectively queried our prospectively database of patients treated with HoLEP or RASP between 2017 and 2022 among two high-volume centers. PSM was applied based on the International Prostate Symptom Score (IPSS) questionnaire, prostate volume and max-flow rate. All procedures were performed by a single surgeon per center. Outcomes were assessed at 1, 3, and 6-month postoperatively and therefore annually. Trifecta definition was used to assess "success" in surgical procedures and was defined as the contemporary presence of: a) no postoperative complications within the first postoperative month; b) 1-month postoperative Qmax >15 ml/s and c) no urinary incontinence at 3-month evaluation. RESULTS: Overall, 48 HoLEP and 47 RASPs were matched. Operative time, hospitalization time (median 4 vs 5 days) and catheterization time (median 3 vs 2 day) were found to be shorter in the HoLEP group as compared to the counterpart (p < 0.05). Early postoperative complication rate was also lower in the HoLEP cohort (6.2% vs 12.6%; p = 0.03) as well as postoperative haemoglobine blood level drop (1.4 vs 2.4 g/dL; p = 0.03). On the other hand, postoperative antegrade ejaculation (55.3% vs 6.8%) 1-month max flow (median 28 vs 24 ml/sec) and continence rates (0% vs 20.8%) favored RASP (p < 0.05). Overall, Trifecta rate was similar in the two groups (76.1% vs 82.6%). CONCLUSION: Both HoLEP and RASP are safe and effective treatments for symptomatic BPH. HoLEP demonstrated to have lower perioperative risks while is affecting by a higher probability of transient early UI. On the other hand, RASP is more effective in reducing postoperative ejaculatory dysfunction.
引用
- Grosso AA, Amparore D, Di Maida F, et al. Comparison of perioperative and short-terms outcomes of en-bloc Holmium laser enucleation of the prostate (HoLEP) and robot-assisted simple prostatectomy: a propensity-score matching analysis. Prostate Cancer Prostatic Dis. 2023. PMID: 37857831. doi:10.1038/s41391-023-00743-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。